Fig. 7.

SIL@T can induce ICD, activate immune response, inhibit the growth of metastatic tumors in Co-BM-mice and prolong the survival of Co-BM-mice. A) Treatment and monitor schedule for SIL@T therapy. B) The change curve of body weight after administration of different preparations (n = 6). C) The signal change curve of metastasis tumor after administration of different preparations (n = 4, One-way ANOVA, *P < 0.05, **P < 0.01). D) Survival curves of Co-BM-mice after administration of different formulations (n = 6). E) WB results of metastatic HMGB1. F) WB results of metastatic CRT. G) WB results of metastatic pSTAT3.